Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 7/20 | 0.56 |
| ▸ | HRH1 | P35367 | 3/20 | 0.56 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 8/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748633 | 0.93 | NSD2 (0.57) | SSTR5HRH1NSD2CNR1CNR2 | |
| SCHEMBL1748201 | 0.92 | SSTR5 (0.63) | SSTR5HRH1NSD2CNR1HTR2B | |
| SCHEMBL1748696 | 0.91 | SSTR5 (0.56) | SSTR5HRH1NSD2CNR1HTR2B | |
| SCHEMBL1748577 | 0.91 | CNR1 (0.57) | SSTR5HRH1NSD2CNR1HTR2B | |
| SCHEMBL1748454 | 0.90 | SSTR5 (0.69) | SSTR5HRH1NSD2CNR1HTR2B | |
| SCHEMBL1748335 | 0.90 | NSD2 (0.58) | SSTR5HRH1NSD2CNR1HTR2B | |
| SCHEMBL1748930 | 0.88 | NSD2 (0.56) | SSTR5HRH1NSD2CNR1HTR2B | |
| SCHEMBL1878027 | 0.86 | KDM4E (0.66) | SSTR5HRH1NSD2HTR2BMEN1 | |
| SCHEMBL1748437 | 0.85 | NSD2 (0.55) | SSTR5HRH1NSD2CNR1HTR2B | |
| SCHEMBL27769533 | 0.85 | NSD2 (0.53) | SSTR5HRH1NSD2CNR1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968568-B2 | [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2044054-B1 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | CHRIST ANDREAS D | 2010-03-18 | — | — | US | disclosed |
| US-7674804-B2 | Pyrimidine and quinazoline derivatives as SST5 modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2044054-A2 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. Hoffmann-Roche AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
| WO-2008000692-A2 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | SSTR5, SSTR3, NPY5R | SSTR5 1/4885HRH1 158/4885NSD2 3810/4885 |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | SSTR5, SSTR3, NPY5R | SSTR5 1/4885HRH1 158/4885NSD2 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.